MX9605128A - Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos. - Google Patents

Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.

Info

Publication number
MX9605128A
MX9605128A MX9605128A MX9605128A MX9605128A MX 9605128 A MX9605128 A MX 9605128A MX 9605128 A MX9605128 A MX 9605128A MX 9605128 A MX9605128 A MX 9605128A MX 9605128 A MX9605128 A MX 9605128A
Authority
MX
Mexico
Prior art keywords
tachykinine
neurokinine
antagonists
compounds
concerns
Prior art date
Application number
MX9605128A
Other languages
English (en)
Other versions
MXPA96005128A (es
Inventor
Gerd Schnorrenberg
Franz Esser
Horst Dollinger
Birgit Jung
Georg Speck
Erich Burger
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4445939A external-priority patent/DE4445939A1/de
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of MXPA96005128A publication Critical patent/MXPA96005128A/es
Publication of MX9605128A publication Critical patent/MX9605128A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

El invento se refiere a nuevos derivados de aminoácidos de la formula general (I), y sus sales farmacéuticamente aceptables, en que el grupo B es - A2 - NR2R3o R5, en que R1, A1, A2, R2, R3, R5 y R11 poseen los significados indicados en la memoria descriptiva, así como su preparacion y utilizacion. Los nuevos compuestos son valiosos antagonistas de neuroquinina (taquinina).
MX9605128A 1994-05-07 1995-05-04 Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos. MX9605128A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4416255 1994-05-07
DEP4416255.3 1994-05-07
DE4445939A DE4445939A1 (de) 1994-05-07 1994-12-22 Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen (II)
DEP4445939.4 1994-12-22
PCT/EP1995/001691 WO1995030687A1 (de) 1994-05-07 1995-05-04 Neurokinin (tachykinin)-antagonisten

Publications (2)

Publication Number Publication Date
MXPA96005128A MXPA96005128A (es) 1997-08-01
MX9605128A true MX9605128A (es) 1997-08-30

Family

ID=25936418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605128A MX9605128A (es) 1994-05-07 1995-05-04 Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.

Country Status (20)

Country Link
US (2) US5712273A (es)
EP (1) EP0804463A1 (es)
JP (1) JPH09512806A (es)
CN (1) CN1147260A (es)
AU (1) AU690275B2 (es)
BG (1) BG100946A (es)
CA (1) CA2189764A1 (es)
CZ (1) CZ325496A3 (es)
EE (1) EE9600186A (es)
FI (1) FI964473A0 (es)
HR (1) HRP950276A2 (es)
HU (1) HUT75708A (es)
IL (1) IL113625A0 (es)
MX (1) MX9605128A (es)
NO (1) NO964700L (es)
NZ (1) NZ285750A (es)
PL (1) PL317127A1 (es)
RO (1) RO115355B1 (es)
SK (1) SK142696A3 (es)
WO (1) WO1995030687A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59309867D1 (de) * 1992-09-03 1999-12-16 Boehringer Ingelheim Pharma Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE19541283A1 (de) 1995-11-06 1997-05-07 Boehringer Ingelheim Kg Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19623950A1 (de) * 1996-06-15 1997-12-18 Boehringer Ingelheim Kg Pharmazeutische Zubereitung in Form von Liposomen
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
CA2362290A1 (en) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
WO2001035964A1 (en) 1999-11-18 2001-05-25 Antexpharma, Inc. Substituted 1-benzazepines and derivatives thereof
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2003087069A2 (en) * 2002-04-09 2003-10-23 Eli Lilly And Company Dipeptidic growth hormone secretagogues
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7238560B2 (en) * 2004-07-23 2007-07-03 Cree, Inc. Methods of fabricating nitride-based transistors with a cap layer and a recessed gate
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
EP1904069B1 (en) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3414239A2 (en) 2016-02-05 2018-12-19 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
GB9023116D0 (en) * 1990-10-24 1990-12-05 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
DE59309867D1 (de) * 1992-09-03 1999-12-16 Boehringer Ingelheim Pharma Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Also Published As

Publication number Publication date
PL317127A1 (en) 1997-03-17
NO964700D0 (no) 1996-11-06
SK142696A3 (en) 1997-06-04
EP0804463A1 (de) 1997-11-05
BG100946A (en) 1997-07-31
NO964700L (no) 1996-11-06
AU2524995A (en) 1995-11-29
EE9600186A (et) 1997-08-15
AU690275B2 (en) 1998-04-23
US5700827A (en) 1997-12-23
FI964473A (fi) 1996-11-07
HRP950276A2 (en) 1997-04-30
IL113625A0 (en) 1995-08-31
RO115355B1 (ro) 2000-01-28
US5712273A (en) 1998-01-27
WO1995030687A1 (de) 1995-11-16
HUT75708A (en) 1997-05-28
JPH09512806A (ja) 1997-12-22
FI964473A0 (fi) 1996-11-07
CA2189764A1 (en) 1995-11-16
CZ325496A3 (en) 1997-09-17
CN1147260A (zh) 1997-04-09
NZ285750A (en) 1998-08-26
HU9603082D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
BG103413A (en) Derivatives of sulphinic acid, their production and application
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
BG101112A (en) The use of heterocyclic compounds
AP9701041A0 (en) Pyridylpyrrole compounds.
BG106586A (en) Pyrazolopyramidines as therapeutic agents
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
BG103251A (en) Oxydiazols, methods for their preparation and application as medicamentous forms
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
BG101110A (en) Substituted pyrimidine compounds and their application
BG105783A (en) Triazole compounds with dopamine-d3-receptor affinity
MY133392A (en) Novel substituted pyrazole derivatives
AU6645998A (en) Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
MX9803954A (es) Derivados de aminoacidos, composiciones farmaceuticas que contienen estos compuestos y procesos para prepararlos.
MX9805181A (es) Derivados de lactona a partir de derivados de 17.beta- carboxi, carbotio y amida androstano.
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
UA50762C2 (uk) Похідні арилгліцинаміду та фармацевтична композиція
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
CY2198B1 (en) 1-Aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
MX9702203A (es) Derivados de pirazolil-pirazol substituidos, procedimientos para su preparacion y su uso como agentes con accion herbicida.
PL316870A1 (en) Derivatives of 5-heterocyclo 1,5-benzodiazepine
MY132057A (en) Quinoxalinones, a process for their preparation and their use
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
MX9700813A (es) Nuevos derivados 3-substituidos de 3h-2,3-benzodiazepina, su preparacion y su uso como medicamentos.